TELA Bio (TELA) Piper Sandler 36th Annual Healthcare Conference summary

Market dynamics and industry trends

• IV shortages and hurricane disruptions have not significantly impacted recent performance, but inventory workdowns and supply chain adjustments may affect results later in the quarter, especially in general surgery and hernia repair, which are sensitive to such perturbations.

• A major polypropylene mesh settlement is expected to drive a market shift from permanent synthetic meshes to resorbable polymers and alternative solutions, with a $2 billion settlement influencing 80% of the hernia implant market over the next few years.

• The transition away from polypropylene is expected to accelerate starting next year, with momentum building over the following three to four years, mirroring the OB-GYN mesh market shift.

• Hospitals and contracting groups are considering reclassification of products to avoid volume-based discounts that favor incumbent suppliers, potentially opening more market share.

• International growth, especially in the UK and Europe, is strong, with shared decision-making models between patients and surgeons supporting adoption.

Product and sales strategy

• The company is positioned as one of four main beneficiaries of the polypropylene market transition, offering a reinforced tissue matrix that is compatible with robotic surgery and competitively priced.

• New product launches, such as the IHR suite for inguinal hernia and fixation devices, are broadening the portfolio and shifting perception from a niche biologics provider to a comprehensive hernia repair company.

• PRS (Plastic and Reconstructive Surgery) is growing faster than hernia products due to a smaller base and is supported by emerging clinical data and ongoing regulatory studies.

• The sales force has been restructured to increase productivity, with a focus on adding associate reps and reducing support staff, driving deeper penetration in existing territories.

• Compatibility with Intuitive Surgical's robotic platforms is a strategic focus, with product design and data collection tailored for robotic procedures.

Financial outlook and operational efficiency

• Q4 is expected to see a $4 million sequential revenue increase, driven by seasonal factors, physician and patient behavior, and deepening usage within hospital systems.

• Operating expense reductions of $5–10 million are anticipated in 2025, primarily from sales force restructuring and support staff optimization.

• The company expects to achieve operating income profitability at quarterly revenues of $30–35 million, possibly even lower.

• Recent capital raise provides a financial cushion and signals to investors that additional funding is not immediately necessary.

• Top-line growth above 25% is expected to continue into 2025, with further upside possible from new territories, products, and GPO contracts.